Update launch ChondroCelect (Tigenix) and status of reimbursement applications http://tiny.cc/FRRhS
posted 1 day ago
FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.
Website: http://www.tibotec.com
Email:
Phone: +32 15 29 31 00
Flandersbio Member
More address details
Tibotec is a pharmaceutical research and development company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need.
Our mission is to be a world leader in the discovery and development of unique and innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.
Recognised as one of the companies at the forefront of HIV research, Tibotec has three antiretroviral compounds in clinical development. TMC114, a novel protease inhibitor and TMC125, a new and unique non-nucleoside reverse transcriptase inhibor (NNRTI) have been approved by FDA in US and EMEA for the European Union and several other countries around the world. TMC278, another novel NNRTI is in Phase III development. Furthermore does the company also have an anti-tuberculosis compound from a novel class in early development, and several active discovery programs in HIV, Hepatitis C and other life-threatening infectious diseases.
Tibotec is committed to improving medical care as well as the quality and longevity of life for patients.
TMC114 (darunavir), TMC 278 (rilpivirine), TMC125 (etravirine)
Address:
Generaal De Wittelaan L11 B3
2800
Mechelen
Belgium
Route: Via Google Maps
Website: http://www.tibotec.com
Phone: +32 15 29 31 00
Fax: +32 15 28 63 47
Foundation date: 7/1994
Email:
Sorry, to find this company's location on Google Maps, Javascript is required.
